Lisa Graver
Vermögen: 117 143 $ am 30.06.2026
Vermögen: 117 143 $ am 30.06.2026
Currently, Lisa Graver is Chief Executive Officer at Norwich Pharmaceuticals, Inc., Chief Executive Officer at Alvotech starting in 2026, and Director at Alvotech hf.
Formerly, Ms. Graver was Chief Executive Officer at Alvogen, Inc. from 2010 to 2025, Chief Executive Officer at Alvogen Pharma US, Inc., Senior Director & VP-Intellectual Property at Actavis, Inc. from 2006 to 2008, Associate at Kirkland & Ellis LLP, and President at Almaject, Inc. Education includes undergraduate studies at the University of Lakehead and graduate studies at Case Western Reserve University School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ALVOTECH 0,01 % | 06.03.2026 | 31.746 ( 0,01 % ) | 117 143 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ALVOTECH | Vorstandsvorsitzender | 01.03.2026 |
Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides contract manufacturing and clinical services for the pharmaceuticals industry | Vorstandsvorsitzender | - |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
Alvogen, Inc.
Alvogen, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Vorstandsvorsitzender | 01.12.2025 |
Alvogen Pharma US, Inc.
Alvogen Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Vorstandsvorsitzender | 01.12.2025 |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures generic, brand and biologic pharmaceutical products | Corporate Officer/Principal | 01.01.2008 |
Almaject, Inc.
Almaject, Inc. Pharmaceuticals: GenericHealth Technology Engages in development, acquisition and commercialization of injectable generic pharmaceutical products | Präsident | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Operates as a law firm | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures generic, brand and biologic pharmaceutical products | Health Technology |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Operates as a law firm | Commercial Services |
University of Lakehead
University of Lakehead Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Norwich Pharmaceuticals, Inc.
Norwich Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides contract manufacturing and clinical services for the pharmaceuticals industry | Health Technology |
Alvogen, Inc.
Alvogen, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Alvogen Pharma US, Inc.
Alvogen Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Case Western Reserve University School of Law
Case Western Reserve University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Almaject, Inc.
Almaject, Inc. Pharmaceuticals: GenericHealth Technology Engages in development, acquisition and commercialization of injectable generic pharmaceutical products | Health Technology |
Alvotech
Alvotech BiotechnologyHealth Technology Develops biologic medicines | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen